Method of treating idiopathic pulmonary fibrosis
AssigneeMediciNova, Inc.
InventorsKazuko MATSUDA, Yuichi IWAKI
Life of this patent
Estimating the term…
Abstract
A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for inhibiting or treating idiopathic pulmonary fibrosis, conditions leading to or arising from it, and/or negative effects of each thereof.
Claims21
A method of treating a patient diagnosed with idiopathic pulmonary fibrosis (IPF), the method comprising administering to the patient an effective amount of a compound of Formula (I), a metabolite of the compound of Formula (I), an ester of the compound of Formula (I), or a metabolite of the ester of the compound of Formula (I):
- or a pharmaceutically acceptable salt of each of the foregoing, wherein m is an integer from 2 to 5 inclusive, and n is an integer from 3 to 8 inclusive, X1 and X2 each independently represent sulfur, oxygen, a sulfinyl group or a sulfonyl group, provided that X1 and X2 are not simultaneously oxygen, wherein the effective amount of the compound is about 100 mg to about 4000 mg/day.
A method of treating a patient diagnosed with IPF, the method comprising administering to the patient an effective amount of a compound of Formula (IA), a metabolite of the compound of Formula (IA), an ester of the compound of Formula (IA), or a metabolite of the ester of the compound of Formula (IA):
- or a pharmaceutically acceptable salt of each of the foregoing, wherein the effective amount of the compound is about 100 mg to about 4000 mg/day.
21-30. (canceled)
Dependencies are inferred from the claim text.